Biofourmis is a global leader in providing advanced technology and clinical support for Care@Home and digital therapies.

Biofourmis is pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

Biofourmis was founded in 2015 by Kuldeep Singh Rajput and Wendou Niu. The company is headquartered in Singapore and Boston, Massachusetts, with offices in Bangalore, India and Zurich, Switzerland.

Biofourmis utilizes machine learning, integrated technology and an FDA-cleared analytics engine to streamline connections between patients and care teams, leading to better outcomes for all.

Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics’ product pipeline across multiple therapeutic areas—including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.

Biofourmis has formed key collaborations with healthcare stakeholders, including its membership in the American Heart Association's Center for Health Technology & Innovation's Innovator Network to deliver personalized software-based interventions.

Biofourmis is backed by General Atlantic, SoftBank Vision Fund 2, Intel Capital, CVS Health, Sequoia India, MassMutual Ventures, Openspace Ventures, Aviva Ventures, EDBI, and others. The company raised an additional $20M, this is an extension of their previous $300M raised in Apr 2022, bringing the round total to $320M. The additional investment brings Biofourmis' total funding to $463.6M to date. Biofourmis was valued at $1.3B after the 1st tranche of Series D in Apr 2022.